MetaCap

Agenus (AGEN) vs Precision BioSciences (DTIL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Precision BioSciences (DTIL) has outperformed Agenus (AGEN) over the past year, gaining 48.0% versus a gain of 41.5%. Over five years, AGEN leads with a -90.6% price change compared with -97.2% for DTIL. Precision BioSciences is the larger company by market cap ($282.5 million vs $270.1 million), about 1.0 times the size, while Agenus is growing revenue faster (+10.4% vs -50.1%).

On valuation, Agenus trades at a lower trailing P/E (26.0x vs 29.6x for Precision BioSciences). Agenus converts more of its revenue into profit, with a net margin of -2.7% versus -133.4%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AGEN+41.47%DTIL+48.00%
+144%+50%-43%
Nov 21, 20251 yearNov 20, 2026
AGEN-91.28%DTIL-97.36%
+8%-48%-104%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AGEN versus DTIL key metrics
MetricAGENDTIL
Share price$5.97$7.40
Market cap$270.12M$282.46M
1-day change-2.77%+7.09%
YTD return+90.13%+77.88%
1-year return+41.47%+48.00%
5-year return-90.58%-97.23%
P/E ratio (TTM)25.9629.60
EPS (TTM)$0.23$0.25
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$114.20M$34.26M
Revenue growth (YoY)+10.37%-50.12%
Net income (latest FY)$-3.08M$-45.72M
Gross margin99.11%—
Operating margin-17.66%-152.19%
Net margin-2.70%-133.45%
52-week high$10.31$11.29
52-week low$2.71$3.53
Distance from 52-week high-42.10%-34.46%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+352.26%+297.30%
Average volume905.17K319.79K
Shares outstanding45.25M38.17M
Employees8169
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Agenus is more profitable, keeping -2.7 cents of every revenue dollar as net income versus -133.4 cents for Precision BioSciences.
  • Agenus grew revenue faster in its latest fiscal year (+10.37% vs -50.12%).

About Agenus

AGEN stock →

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees

About Precision BioSciences

DTIL stock →

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 69 employees

AGEN vs DTIL FAQ

Which is bigger, Agenus or Precision BioSciences?

Precision BioSciences (DTIL) is larger, with a market capitalization of $282.46M compared with $270.12M for Agenus (AGEN).

Which stock has performed better over the past year, AGEN or DTIL?

DTIL returned +48.00% over the past 12 months, compared with +41.47% for AGEN (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, AGEN or DTIL?

AGEN has the lower trailing P/E at 26.0, versus 29.6 for DTIL. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Are Agenus and Precision BioSciences in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons